ABSTRACT. Objective. To evaluate the safety and immunogenicity of 6 different acellular pertussis vaccines combined with diphtheria and tetanus toxoids (DTaP) and with 1 licensed whole-cell pertussis vaccine (DTwP) as a fifth dose in children who had previously received the same DTaP, a different DTaP, or DTwP as primary and fourth-dose vaccinations.
tions, but the statistical power to detect differences was limited by sample size.
Significant increases in antibodies directed against the included antigens were observed for all DTaP vaccines in paired pre-and post-fifth dose sera. Post-fifth dose antibody concentrations differed significantly among the DTaP vaccines. Some children in the study showed an antibody response to an antigen not reported to be in the DTaP vaccine.
Conclusion ABBREVIATIONS. DTaP, diphtheria and tetanus toxoids combined with acellular pertussis vaccine; DTwP, diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine; DTP, DTwP or DTaP; NIAID, National Institute of Allergy and Infectious Diseases; PT, pertussis toxin; FHA, filamentous hemagglutinin; PRN, pertactin; FIM, fimbriae; ELISA, enzyme-linked immunosorbent assay; EU, ELISA units; GMC, geometric mean concentration. D uring the past 2 decades, several acellular pertussis vaccines combined with diphtheria and tetanus toxoids (DTaP) have been developed and evaluated for safety and efficacy, and recently 4 DTaP vaccines have been licensed for use in the United States. In the routine childhood immunization schedule, DTaP vaccines are a preferred alternative to traditional whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids (DTwP) because they are less reactogenic. [1] [2] [3] [4] [5] [6] DTaP vaccines have been in use in the United States as the fourth-and fifth-dose boosters for children 15 to 20 months of age and 4 to 6 years of age, respectively, for several years. 5, 6 Initially, these products were approved for administration after a primary series of DTwP injections; however, with the recent licensure of DTaP vaccines for use in infants, there will be, in the near future, children eligible for fifth-dose immunization for whom all previous immunizations were DTaP. This is the first and only study to evaluate comparatively the safety and immunogenicity of a fifth consecutive dose of different DTaP vaccines.
We conducted a double-blinded, multicenter clinical trial of 6 DTaP vaccines and 1 US licensed DTwP vaccine when given as a fifth-dose booster. All children enrolled had already received 4 doses of 1 of the 6 DTaP vaccines included in this study, 1 of 7 other DTaP vaccines that had been included in earlier National Institute of Allergy and Infectious Diseases (NIAID) multicenter acellular pertussis vaccine trials, [7] [8] [9] or a licensed DTwP vaccine. The primary goal was to evaluate the safety and immunogenicity of a fifth dose in those children who had received 4 previous doses of the same DTaP product. Additionally, data on the safety and immunogenicity of DTaP vaccines when given as a fifth-dose booster after previous vaccinations with a variety of DTaP products were generated.
METHODS

Vaccines
DTaP vaccines containing 2 to 4 pertussis components plus diphtheria and tetanus toxoids were included in the study (Table  1 ). All the DTaP vaccines included inactivated pertussis toxin (PT) and filamentous hemagglutinin (FHA), and some included pertactin (PRN) and/or fimbriae (FIM).
Subjects
Healthy children 4 to 6 years of age who had completed earlier NIAID multicenter acellular pertussis vaccine trials 7-9 that compared 2 DTwP and several DTaP vaccines, administered at 2, 4, 6, and 15 to 20 months of age were offered participation. Institutional review boards at each collaborating institution approved the protocol. Informed consent was obtained from parents or guardians before enrollment. No subjects with contraindications or precautions to immunization as specified in the Report of the Committee on Infectious Diseases of the American Academy of Pediatrics 6 were enrolled, and only those who received all 3 primary study doses in the earlier trial 7 were eligible to participate. Some subjects had not participated in the fourth-dose study 9 ; all these individuals had received a licensed DTaP or DTwP vaccine for their fourth-dose booster.
Study Design
The vaccines were evaluated at 5 study sites: Baylor College of Medicine, Houston, Texas; University of Maryland School of Medicine, Baltimore, Maryland; University of Rochester, Rochester, New York; St Louis University School of Medicine, St Louis, Missouri; and Vanderbilt University School of Medicine, Nashville, Tennessee. When determining the vaccine to be administered at fifth dose, if possible, children received the same product as they had at fourth dose. When the product given for the fourth dose was not available for fifth dose, children who had received the Connaught Laboratories Ltd 3-component vaccine 7, 9 at fourth dose, received CLL-4F 2 and children who received the SmithKline Beecham 2-component vaccine, 7, 9 at fourth dose, received SKB-3P. All other children were randomly assigned to receive CLL-4F 2 , LPT-4F 1 , CB-2, PM-2, or BSc-3P. Thus, there were children who received 5 doses of the same DTaP product (same AAA group), children who received DTaP for all 5 doses but not all 5 were the same product (mixed AAA group), children who received DTwP for all 5 doses (WWW group), and children who received a priming series with DTwP followed by DTaP at fourth and fifth dose (WAA group) ( Table 2) . A small number of children received uncommon immunization schedules (WAW or AWA) and were excluded from additional analysis.
Double-blinding procedures were as previously described. 7, 9 Study vaccinations were given in the arm (.5 mL. with 1-inch needles). Children were given oral polio vaccine concurrently.
Reaction Assessment
Reactions were assessed as previously described, 8 
Serology
For all sera, antibodies to PT, FHA, PRN, and FIM were measured by enzyme-linked immunosorbent assay (ELISA) at the University of Rochester using methods adapted from those used for the primary series trial. 10 Using the reference line calculation method, 11 results were expressed in ELISA units/mL (EU/mL) based on US reference pertussis antiserum (human), lots 3 and 4. Lower limits of detection for the University of Rochester laboratory were 2 EU/mL for PT and FHA and 3 EU/mL for PRN and FIM antibody assays. For consistency, the same lower limit of detection (6 EU/mL) was used as in previous publications when calculating fourfold increases in PRN antibody. 7, 9 The 4 ELISAs also were performed at the Center for Biologics Evaluation and Research on a subset of 125 sera. When comparing the 4 ELISAs performed at the University of Rochester and the Center for Biologics Evaluation and Research laboratories, the geometric mean of ratios of individual values ranged from .67 to 1.5, indicating generally similar quantitative results. Spearman rank correlation 14 respectively. Tetanus and diphtheria antitoxin concentrations were expressed in U/mL using international reference sera that had been calibrated using tetanus Antitoxin human immunoglobulin, reagent 76/589 and diphtheria antitoxin human serum, reagent 91/534. Both were obtained from the National Institute for Biological Standards and Control (London, UK).
Statistical Analysis
Reaction Data
Data are presented for 5 common reactions (fever, irritability, injection site redness, swelling, and pain) that were used previously in comparisons of DTaP and DTwP vaccines 15 using methods of tabulation described previously. 8 Incidence and severity of reactions in different groups were compared using appropriate nonparametric tests. 12 Within-group comparisons of reactions after the fourth and fifth vaccinations in the same individuals used the Wilcoxon signed-rank test. 12 For these nonparametric tests, ranks were calculated as described previously. 8 
Serology Data
Serologic analyses included children who had been vaccinated at 4 to 6 years of age and from whom serum had been collected both preimmunization and postimmunization. For calculations of geometric mean antibody concentrations (GMCs) and 95% confidence intervals, results lower than the minimum detectable level for the assay were assigned a value of one half of the minimum detectable level. For calculation of fold-rises, results lower than the minimum detectable level were assigned the minimum detectable level. Within-group comparisons of preimmunization and postimmunization values included both a sign test 12 and a paired t test on the logarithms of antibody levels. The 2 methods gave comparable results, and we report the results of the paired t test. Amonggroup comparisons used Duncan's multiple-range test to determine groups that did not differ significantly. 16 Calculations were performed with SAS software (SAS Institute, Inc, Cary, NC). Unless stated otherwise, P values were not adjusted for multiple testing beyond any adjustment inherent in the test procedures; however, a Bonferroni adjustment was used in pairwise comparisons of reaction occurrences between recipients of a specific acellular vaccine at the fifth dose who did and did not receive that same vaccine at all previous injections. 16 A P value Ͻ.05 was considered statistically significant.
RESULTS
A total of 351 children received a fifth dose of DTaP or DTwP in the current study. Of these children, 327 fell into 4 groups of primary interest: same AAA (5 doses of the same DTaP; n ϭ 121); mixed AAA (5 doses of DTaP, but not all with the same product; n ϭ 147); WAA (DTwP primary series, DTaP boosters; n ϭ 49); and WWW (5 doses of DTwP, but not necessarily all with the same product; n ϭ 10). The distribution of the vaccinees in these groups is shown in Table 2 . Of the children, 24 received a dose of DTaP or DTwP but could not be placed into 1 of the above categories; these children were not included in this analysis. Two thousand three hundred forty-two children were enrolled in the primary NIAID series trial 7, 8 and 1374 participated in the fourth-dose trial. 9 The attrition of enrollees in this study occurred primarily because children had already received their fifth dose of DTaP or DTwP before initiation of the study or were not enrolled by the parent because of objections to blood collections (with several licensed DTaP vaccines available as an option). All children in the current study received the fifth vaccination at 4 to 6 years of age and all postvaccination sera were obtained between 21 and 81 days after immunization.
Adverse Reactions
For the 4 vaccination sequences of interest, Table 3 gives rates of systemic (fever and irritability) and local (redness, swelling, and pain) reactions after the fifth dose. There was very little fever Ͼ100°F. Any irritability, redness, swelling, and pain, including moderate and severe pain, tended to occur more frequently in the WWW group. However, there were no distinct differences by vaccine group in the occurrence of large areas of injection site redness and swelling. Large swelling or redness among those children who received 5 doses of the same DTaP http://www.pediatrics.org/cgi/content/full/105/1/e11vaccine was not uncommon with swelling Ͼ50 mm occurring in 15 of 120 (12.5%) children and redness Ͼ50 mm in 20 of 120 (16.7%) children.
Adverse reactions developed in a similar pattern with respect to time after injection for the 4 groups. The temporal pattern was similar to that reported after fourth dose. 9 Irritability and pain tended to be reported most frequently on the first evening, whereas redness and swelling Ͼ20 mm were reported most frequently on the second or third evening. Fever was infrequent and generalizations regarding temporal pattern cannot be made. In general, the rates and severity of reactions were decreasing by the end of the third day.
In the primary series 8 and fourth-dose booster 9 trials, a significant trend toward an increased prevalence of injection site reactions with successive vaccinations for both DTaP and Lederle DTwP was observed. To assess whether this trend for intensifying local reactions would continue with the fifth-dose booster, reaction rates between the fourth-dose booster 9 and the fifth-dose boosters were compared (Table 4) . Because the incidence of reactions from dose to dose for an individual is not independent, 17 only the subset of participants from the fourth-dose trial who participated in the current study and who received the same DTaP product at fourth and fifth doses and for whom complete reaction data were available were included. For the same AAA group, there were significant differences for all reaction categories between the fourth and the fifth doses. There were decreases in the 2 systemic reactions, temperature and irritability, but increases for the injection site reactions, swelling, redness, and pain. In the mixed AAA group, there was a decrease in fever and increases for redness and swelling. In the WAA group, there were increases in redness and in pain.
Among the 121 children in the same AAA group, there were between 12 and 29 who received 5 doses of any particular DTaP product. The reaction rates for the 6 individual DTaP products are shown in Table 5 (upper half). Significant differences among the 6 vaccine groups were observed for pain but not for the other 4 reactions. Table 5 (lower half) reports for each DTaP the reactions for those children who had received other products during the 5-dose series (mixed AAA or WAA). Product specific analyses were performed comparing reactions in the same AAA group (Table 5 upper half) to those in the mixed schedule groups (mixed AAA or WAA groups, Table 5 lower half). There were no significant differences when adjustment was made for the multiple comparisons. The occurrence of anorexia, vomiting, and drowsiness was uncommon after a fifth dose of DTaP or DTwP vaccine, and no differences were observed when vaccine groups were analyzed in a like manner.
Special attention was focused on monitoring for more severe reactions. None of the children in our study experienced a seizure, hypotonic/hyporesponsive episode, or other uncommon events associated with pertussis vaccination. No child had a fever Ͼ103.0°F. Severe irritability was reported for only 2 children. As noted above, redness Ͼ50 mm, swelling Ͼ50 mm, and severe pain occurred after DTaP im- Table 2 and "Methods" section for description of study groups. ‡ Significant differences among 4 groups for pain (P Ͻ .05).
munization (Tables 3-5) , including whole-arm swelling in 5 children (Rennels MB, Deloria MA, Pichichero ME, et al, unpublished data).
Serologic Response
The primary immunogenicity data for this study are provided by those individuals in the same AAA groups (Table 6 ). Antibody concentrations before the fifth-dose immunizations (data available on request) were lower than those observed 1 month after the fourth-dose vaccination, 9 although quantitative comparisons must be made cautiously because assays after the fourth dose were performed in a different laboratory. For all 6 DTaP vaccines, the postimmunization GMCs were significantly higher than the preimmunization GMCs for all antigens reported to be in the vaccines. Table 6 also presents the proportion of children with at least a fourfold increase in antibody concentration. In those children who received different DTaP products, an antibody response was observed to the pertussis antigens contained in the DTaP vaccine received at the fifth dose (Table 5 ). For all 6 DTaP vaccines, the postimmunization GMCs were significantly higher than the preimmunization GMCs for those antigens reported to be in the vaccines.
In mixed AAA groups, the composition of the vaccine received at fifth dose was often different from that received for previous doses. As a consequence, there were some children who received a specific antigen at fifth dose without receiving that antigen in the 4 previous immunizations. To gain insight into the response that would occur in this circumstance, we separated the mixed AAA group into those children who received a particular antigen for the first time and those children who had received that antigen in 1 or more of the preceding DTaP immunizations. These results are presented for FHA, PRN, and FIM in Table 7 . Analyses were not performed for PT antibody because all children had received inactivated PT in their previous doses. As anticipated, the antibody response was generally higher in children who had been exposed to that antigen in 1 or more of the previous vaccinations.
As reported previously, 7,9 some children in the study showed an antibody response to an antigen not reported to be in the DTaP vaccine. For the CB-2 vaccine, 8 of 18 (44%) children in the same AAA group, 2 of 14 (14%) in the mixed AAA group, and 6 of 9 (67%) in the WAA group had a fourfold or greater increase in antibodies to PRN, suggesting that CB-2 contained some PRN. Any quantity of PRN in CB-2, seems to be low however, because none of the children immunized with 3 doses of CB-2 7 and only ϳ10% of the children immunized with 4 doses of CB-2 9 had at least a fourfold rise in PRN antibody. Two of the 80 (3%) children in the same AAA group who received a vaccine without FIM showed a fourfold rise in FIM antibody; 1 had been immunized with CB-2 and 1 with PM-2.
A significant increase in diphtheria and tetanus antibodies was observed in all study groups, including those children who received different products throughout the schedule. All children in this study had antibody concentrations that exceeded the presumed minimum protective levels of .1 U/mL for http://www.pediatrics.org/cgi/content/full/105/1/e11diphtheria 18 and .01 U/mL for tetanus 19 1 month after the fifth dose.
DISCUSSION
Four DTaP products are currently licensed in the United States for primary immunization of infants; the first vaccine was licensed in July 1996. A large number of children who have received DTaP vaccines for the first 4 doses will soon come of age for their fifth dose in the recommended schedule. Several studies have evaluated the safety and immunogenicity of a fifth dose of DTaP vaccines after primary immunization with DTwP vaccines and 2 DTaP vaccines were licensed in 1991 and 1992 for this indication. However, there are very few reports of the safety and immunogenicity of a fifth dose after 4 previous doses of the same DTaP vaccine. Reflecting this absence of data, 3 of the 4 US licensed products have not yet been approved for a fifth dose when the first 4 doses were DTaP. This study took advantage of the opportunity to evaluate the safety and immunogenicity of a fifth dose of 6 different DTaP products in children who had been evaluated in previous studies. This is 1 of few reports on the safety and immunogenicity of a fifth dose of DTaP, and the first to evaluate multiple DTaP products in a schedule that included more than 1 product. Larger product specific studies are being conducted by vaccine manufacturers so that more information can be available before the cohort of children immunized with DTaP for their primary series reach the age for fifth dose.
Combining the results of this study with our earlier publications 8, 9 suggests the overall safety profile for the 5-dose series of DTaP vaccines for the common reactions was better than that observed for 5 doses of DTwP vaccine. No DTaP vaccine was consistently the most or least reactogenic after the fifth dose of a 5-dose series, but sample size limited the statistical power to detect potentially meaningful differences. The fifthdose booster showed a trend for intensifying injection site reactions but not systemic reactions from dose 4 to dose 5. Large injection site reactions, which usually did not limit activity, were not uncommon with overall rates of ϳ1 of every 6 for redness Ͼ50 mm, 1 of every 8 for swelling Ͼ50 mm, and 1 of every 40 for severe pain. These rates were for the cohort of children in the same AAA group combining data from all products. Larger studies may demonstrate that the rates vary for the different DTaP products. Nevertheless, parents should be forewarned about this possibility after fifthdose boosters with DTaP vaccines.
In those children who received 5 doses of the same DTaP product, each of the evaluated DTaP vaccines produced significant increases in antibodies directed against included antigens, but postvaccination antibody concentrations differed significantly among the DTaP vaccines. Because serologic correlates of protection are not known, it is not currently possible to determine whether a greater quantity of antibody generated by 1 vaccine compared with another has clinical relevance.
It is currently recommend that, when feasible, the same DTaP should be used throughout the series. However, there will be circumstances when use of the same product will be impractical, if not impossi- ble. In such cases the Advisory Committee on Immunization Practices recommends continuing the vaccination schedule with the administration of a different DTaP product. There are no published data that report the safety or immunogenicity of schedules that involve the use of more than 1 DTaP product. Several of the experimental DTaP products evaluated in the NIAID Vaccine Treatment and Evaluation Units acellular pertussis trials were not available for the fifth-dose study, giving rise to the opportunity to collect data on the safety and immunogenicity of schedules that involved more than 1 DTaP product. Our study was not designed to evaluate specific mixed schedules and our sample size was small; thus few formal analyses have been performed in this report. Nevertheless, the safety data For all vaccine groups (same AAA, mixed AAA, and WAA), when the vaccine contained an antigen, the post was significantly greater than pre and when the antigen was not present, the post was not significantly greater. The exceptions are: a for CB-2, significant increase in PRN for WAA groups, same AAA, mixed AAA; b for CB-2, significant increase in FIM for GMC antibody from pre to post booster was observed in the same AAA group; and c for PM-2, significant increase in PRN f for GMC antibody from pre to post booster was observed in the same WAA group. For the study groups, the GMCs in preimmunization samples ranged from 2 to 25 EU/mL for PT, 5 to 41 EU/mL for FHA, 4 to 58 EU/mL for PRN, and 2 to 49 EU/mL for FIM. are generally encouraging in that the nature and rates of reactions to DTaP at fifth dose were similar whether the same or different products were used at previous doses. Few definitive conclusions can be made from the immunogenicity of a mixed schedule; however, the data from Tables 6 and 7 suggest that most individuals will respond to the antigens in a DTaP vaccine, although the response for each antigen is likely to be higher if that antigen was contained in previously received doses.
In previous publications, 7,9 evidence was provided that some children produced an antibody response to antigens not reported to be contained in the vaccine. In the current study, a fourfold or greater antibody rise to PRN was observed in some children after 5 doses of CB-2 vaccine, although PRN is not reported to be present in this vaccine. The PRN content of CB-2 seems to be low because of the limited response after 3 or 4 doses. 7, 9 Among the children who were immunized with 1 of the four DTaP vaccines without FIM, fourfold responses to FIM were infrequent, occurring in only 5 of 182 (3%) of subjects. These results suggest that some DTaP products that were reported to lack PRN and/or FIM contain sufficient amounts of these antigens to stimulate an immune response in some individuals that have been primed.
This study has limitations. Although we present P values from formal statistical tests, several factors dictate that they be interpreted with caution. First, the children in the present study represent a small proportion of those in the original randomized trial; 7, 8 thus the results presented herein could in some cases be influenced by selection biases of unknown direction and magnitude. Uncertainty about the representativeness of the study population attributable to the high dropout rate causes a concern about generalization of the findings. Second, small numbers in 1 or more of the groups being compared limit the statistical power of the tests, especially with regard to comparisons of individual DTaP vaccines. Third, primary antibody assays were performed in 3 different laboratories, making precise comparisons of postimmunization antibody concentrations after the fifth dose to those after the third and fourth doses difficult because of variation in absolute quantitation of antibody in different laboratories. 20 This study reports the completion of a series of NIAID acellular pertussis vaccine trials that began with 2342 infants. Of these, 121 children received 5 consecutive doses of the same DTaP product. Following these children over the full series of 5 doses provides insight on the safety and immunogenicity the immunization series. We reach the following conclusions: 1) over the full five-dose series, 7,9 all common reactions occur less frequently after DTaP compared with DTwP; 2) there is an increase in local injection site reactions with each subsequent dose, particularly redness and swelling, but such reactions to the fifth dose do not seem to exceed those typically observed with DTwP vaccines; 21,22 and 3) DTaP vaccines are immunogenic when administered as a fifthdose booster. Because serologic correlates and minimum protective levels of antibody to the studied pertussis antigens have not been established, the clinical relevance of differences in magnitude of antibody responses remains unknown.
